Takeda announces results from phase 4 vedolizumab study in patients with chronic pouchitis published in new england journal of medicine

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today confirmed that the new england journal of medicine (nejm) has published positive data from the phase 4 earnest study of vedolizumab for the treatment of chronic pouchitis. the nejm article is titled “vedolizumab for the treatment of chronic pouchitis”.
TAK Ratings Summary
TAK Quant Ranking